Jun 7 2021

Halberd Corporation Creates Two New and Stronger SARS-CoV-2 Neutralizing Antibodies

By |2021-06-06T20:44:05-04:00June 7th, 2021|Featured, Investor News, News|0 Comments

Demonstrates Greater Binding Affinity Than Previous Antibodies Jackson Center, PA, June 7, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful creation of two new neutralizing antibodies against the Spike Protein of SARS-CoV-2, both with a stronger binding affinity than Halberd’s earlier announced monoclonal antibodies against Covid-19.  Each of these new antibodies bind to different ...

Mar 2 2021

Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater

By |2021-03-01T20:05:18-05:00March 2nd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 2, 2021 – Halberd Corp. (OTC PINK:HALB) has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV 2 Spike protein. Dr. Reyes, Halberd’s Chief Technical Officer, indicated, “Our latest results indicate increased specificity of our second antibody, which ...

Sep 21 2020

Arizona State University/Halberd Corp. Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen Re-Creation!

By |2020-09-20T20:34:28-04:00September 21st, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 21, 2020 – Halberd Corporation (OTC PINK: "HALB") released a progress update on the research being conducted in conjunction with Arizona State University researchers.  Dr. Qiang Chen, ASU’s lead researcher, reports the successful re-creation of the coronavirus spike protein disease antigen in laboratory research. With this breakthrough, Dr. Chen’s team will ...

Go to Top